25 LLC’s Abeona Therapeutics ABEO Stock Holding History

25 LLC’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5	Closed	-$20	–	40
2023 Q2	$20	Hold	5	–	–	﹤0.01%	615
2023 Q1	$16	Buy	+5	New	+$13	﹤0.01%	509

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

25 LLC's ABEO Position: Q3 2023 in Review

25 LLC sold out of Abeona Therapeutics (ABEO) in Q3 2023, closing a stake of 5 shares — an estimated $20 sold.

25 LLC first reported a position in ABEO in Q1 2023 and held it in 2 quarters. The position peaked at $20 in Q2 2023. 40 funds tracked by Wall St. Rank hold ABEO as of Q3 2023.

25 LLC reported no remaining Abeona Therapeutics position as of Q3 2023 after selling out during the quarter.
25 LLC sold 5 Abeona Therapeutics shares in Q3 2023, an estimated $20.
25 LLC first reported a position in Abeona Therapeutics in Q1 2023 and held it in 2 quarters.
25 LLC's Abeona Therapeutics position peaked at $20 in Q2 2023.
40 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.